

GALDERMA

EST. 1981

METHODOLOGY NOTES

BACKGROUND

Galderma Nordic AB (Galderma) is a member of Läkemedelsindustriföreningen Lif. Galderma is obliged to publish the data in connection to the interactions with HCPs and HCOs according to Läkemedelsbranschens etiska regelverk, LER (Code). In addition, it is Galderma's responsibility to publish a methodology note as required to summarize the methodologies used in preparing the disclosures and identifying Transfers of Value (TOV). This document supports and explains how Galderma publishes its information in order to comply with the Code in 2023.

Galderma commits to comply with the national transparency laws and regulations and the Code fully. It is our responsibility to make all the possible effort to disclose the TOVs and obtain the consents from the HCPs and applicable HCOs.

SELECTION OF DATA

Galderma reports the data in the standardized template with the following criteria.

Full name:

- HCP: (1) surname and (2) first name provided in the contract with Galderma.
- HCO: full official name (shall be the same name as in the official registry).

HCPs: city of principal practice:

This is the city of principal practice of the HCPs.

HCOs: city where registered:

This is the city where the HCOs are registered.

Country of Principal Practice:

Always mentioned as Sweden.

Principal practice address:

Further details of the address that are not yet included in the preceding columns.

Donations and Grants to HCOs:

The scope is defined as per Article 9 of the Code.

TOV or contribution to costs of events for HCOs:

- Sponsorship agreement with HCOs, third parties appointed by HCOs to manage an event.

Fee for service and consultancy for HCPs or HCOs:

TOV resulting from or related to contracts between Galderma and HCPs or HCOs under which such HCPs or HCOs provide any type of services to Galderma or any other type of funding not covered in the previous categories. Fees, on the one hand, and on the other hand Transfers of Value relating to

expenses agreed in the written agreement covering the activity will be disclosed as two separate amounts.

Aggregate amount attributable to transfers of value to such Recipients (HCPs and/or HCOs):

Total amount of TOV to those HCPs and HCOs where disclosure could not be done for legal reasons

Number of Recipients (HCPs and/or HCOs) in aggregate disclosure:

Total number of HCPs and HCOs where disclosure could not be done for legal reasons.

% of the number of Recipients (HCPs and/or HCOs) included in the aggregate disclosure in the total number of Recipients Disclosed:

Percentage of HCPs and HCOs where disclosure could not be done for legal reasons.

R&D

- TOV referring to Research & Development as defined in Article 12 and Article 1 of the Code.

DATA STANDARDIZATION GUIDANCE

Galderma applies the following approaches when considering:

Applicable National Code:

TOV is disclosed in a manner consistent with the Code.

Consent Management:

Galderma ensures that the consent of TOV disclosure is obtained from the HCPs and applicable HCOs in each engagement according to applicable laws.

For partial consent from the HCPs and applicable HCOs, Galderma publishes the data in an aggregated amount.

The consent from the HCPs and applicable HCOs can be withdrawn during the reporting period. Galderma should respect the correct and most up-to-date consent status.

Cross-border TOVs:

Galderma has worked with all Galderma's affiliates worldwide to capture data relating to TOVs made by them to (i) HCPs with their principal practice in Sweden and (ii) HCOs based in Sweden. Hence, to avoid duplication, only one country always reports such TOVs irrespective of whether the activities occurred outside of Sweden, or the HCPs and HCOs were engaged by other Galderma legal entities. Galderma has used its best endeavours to include all such TOVs within its disclosure report for Sweden.

Currency or Exchange rates used:

The reporting currency is SEK. Foreign currency is converted based on the exchange rate of the month-end accounting report.

Documentation and Retention of Records:

All TOVs are documented pursuant to Article 8 of the Code and Galderma maintains the relevant records of the disclosures made under this Code for a minimum of 5 years after the end of the relevant Reporting Period.

Language of disclosure: Swedish

Reporting format or platform of disclosure:

The report will be published on the corporate website of Galderma with a link to the report in Lif's co-operation database.

Reporting period:

Disclosures shall be made on an annual basis and each reporting period shall cover a full calendar year.

For this reporting period, the TOVs between 1 January 2023 and 31 December 2023 are disclosed. It covers all the TOVs according to the payment date of each TOV in the accounting system, not the date when an HCP or HCO provides the services or the activity in scope occurred. Indirect TOV with payment date outside the reporting period 1 January 2023 to 31 December 2023, but that are connected to a service/activity that took place, and where related payments were made, during the reporting period, are reported according to the date when the indirect TOV were of benefit to the HCP.

Treatment of multi-year contracts:

If Galderma entered in a multi-year contracts with HCPs and/or HCOs, we report the data whenever a financial transaction (TOV) occurred during the reporting year in relation to such multi-year contracts.

VAT and other tax aspects:

All amounts are excluding of VAT.